Drugs and Devices

FDA approves Surfaxin to prevent respiratory distress syndrome in premature infants.

On March 6, the U.S. Food and Drug Administration (FDA) announced the approval of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome in premature infants. Read more.


Related Articles:

Leave a Reply

Your email address will not be published. Required fields are marked *

 

Shares